Biologic Treatment for Hidradenitis Suppurativa

Flood, Kelsey S.; Porter, Martina L.; Kimball, Alexa B.

doi:10.1007/s40257-019-00439-5

Cited by 25 publications

(22 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Again, this is corroborated by the contrasting results of small scale clinical trials of IL-1B and IL-1a blockade in clinical disease [40][41][42] . Lastly, we showed that ITGAL(LFA-1)_ICAM1 interaction is minimally detectable in perilesional epidermis of one patient (Ax1), and not others, confirming that LFA1 blocking may not be effective for HS treatment 43 .…”

Section: Discussionmentioning

confidence: 78%

Defining Epidermal Stem Cell Fate Infidelity and Immunogenicity in Hidradenitis Suppurativa at the Single-Cell Resolution

Marohn

Lin

et al. 2020

Preprint

View full text Add to dashboard Cite

words)Hidradenitis suppurativa (HS) is a severe chronic inflammatory skin disease affecting human apocrine sweat gland-bearing skin regions. One unique feature of HS is the development of keratinized sinus tracts that grow extensively deep in the dermis and are highly immunogenic. Here, we demonstrated that the stem cell fate infidelity exists in the HS sinus tracts, which exhibit features of both surface epidermis and appendages. Using single cell transcriptome analyses, we finely dissected different compartments of the HS epithelium and identified their respective changes in cytokine expression during disease progression and the critical interactions with the immune cells. Together, our work provides advanced understanding of the pathological epidermal remodeling and important implications for HS therapeutics.

show abstract

Section: Discussionmentioning

confidence: 78%

Defining Epidermal Stem Cell Fate Infidelity and Immunogenicity in Hidradenitis Suppurativa at the Single-Cell Resolution

Marohn

Lin

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In our systematic review, we also considered studies evaluating the risk of skin cancers in patients with hidradenitis suppurativa in treatment with adalimumab, the only approved biologic agent for moderate-to-severe hidradenitis ( 71 , 72 ). No articles were found that met the inclusion criteria.…”

Section: Discussionmentioning

confidence: 99%

Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies

et al. 2021

View full text Add to dashboard Cite

Cancer is one of the several comorbidities that have been linked with chronic cutaneous inflammatory diseases namely psoriasis/psoriatic arthritis and hidradenitis suppurativa. Although the chronic inflammatory state, typical of the diseases, may induce pro-tumorigenic effects, the debate whether or not the drugs currently used in clinical practice do in facts increase a patient’s risk of malignancy remains largely unsolved. The therapeutic armamentarium has been greatly enhanced at least in the last two decades with the advent of biologics, a heterogeneous group of laboratory-engineered agents with more in the pipeline, and other targeted small molecules. Among the organ systems, skin results as one of the most commonly affected, non-melanoma skin cancers being the main drug-induced manifestations as side effect in course of these treatments. The objective of the study is to systematically review the cutaneous malignancy risk of the newer therapies through an overview of meta-analyses and observational studies on the topic.

show abstract

“…In terms of HS therapy, biologic agents, particularly targeting tumour necrosis factor alpha (TNFα), are now an integral part of the management of moderate to severe disease [79][80][81]. Although clinical benefit has been reported with several biologics, including infliximab [82], ustekinumab [83] and secukinumab [84], only adalimumab is licensed at present for the treatment of moderate to severe HS.…”

Section: The Cutaneous And/or Gastrointestinal Microbiomes As a Theramentioning

confidence: 99%

The Role of the Cutaneous Microbiome in Hidradenitis Suppurativa—Light at the End of the Microbiological Tunnel

Langan

Recke

Bokor-Billmann

et al. 2020

IJMS

View full text Add to dashboard Cite

The development of next generation sequencing, coupled with advances in bio-informatics, has provided new insights into the role of the cutaneous microbiome in the pathophysiology of a range of inflammatory skin diseases. In fact, it has even been suggested that the identification of specific skin microbial signatures may not only be useful in terms of diagnosis of skin diseases but they may also ultimately help inform personalised treatment strategies. To date, research investigating the role of microbiota in the development of inflammatory skin diseases has largely focused on atopic eczema and psoriasis vulgaris. The role of the microbiome in Hidradenits suppurativa (HS)-also known as acne inversa-a chronic auto-inflammatory skin disease associated with significant morbidity, has received comparatively little attention. This is despite the fact that antimicrobial therapy plays a central role in the treatment of HS. After briefly outlining the clinical features of HS and current treatment strategies, we move on to review the evidence of microbial dysbiosis in HS pathophysiology. We conclude by outlining the potential for metagenomic studies to deepen our understanding of HS biology but more importantly to identify novel and much needed treatment strategies.scoring and the HS severity index. Whilst the precise incidence and prevalence of HS is unclear [8], due partly to the diagnostic difficulty associated with HS and the use of both registry data and self-report questionnaires [9]. Garg et al. reported a prevalence of 0.1% in a US-based population analysis, leading the authors to conclude that HS is an uncommon but not rare disease, with over-representation in young, female and African American patients [10]. The current multi-modal treatment approach includes the use of intralesional steroids, surgical and laser therapy, topical and systemic medical antimicrobial therapy and biologic treatments [11].Sartorius scoring and the HS severity index. Whilst the precise incidence and prevalence of HS is unclear [8], due partly to the diagnostic difficulty associated with HS and the use of both registry data and self-report questionnaires [9]. Garg et al. reported a prevalence of 0.1% in a US-based population analysis, leading the authors to conclude that HS is an uncommon but not rare disease, with over-representation in young, female and African American patients [10]. The current multi-modal treatment approach includes the use of intralesional steroids, surgical and laser therapy, topical and systemic medical antimicrobial therapy and biologic treatments [11].

show abstract

Biologic Treatment for Hidradenitis Suppurativa

Cited by 25 publications

References 98 publications

Defining Epidermal Stem Cell Fate Infidelity and Immunogenicity in Hidradenitis Suppurativa at the Single-Cell Resolution

Defining Epidermal Stem Cell Fate Infidelity and Immunogenicity in Hidradenitis Suppurativa at the Single-Cell Resolution

Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies

The Role of the Cutaneous Microbiome in Hidradenitis Suppurativa—Light at the End of the Microbiological Tunnel

Contact Info

Product

Resources

About